Efficacy of an implantable cardioverter-defibrillator in a neonate with LQT3 associated arrhythmias

Arend D. J. ten Harkel; Maarten Witsenburg; Peter L. de Jong; Luc Jordaens; Marjolein Wijman; Arthur A. M. Wilde

doi:10.1016/j.eupc.2004.09.007

Efficacy of an implantable cardioverter-defibrillator in a neonate with LQT3 associated arrhythmias

Arend D. J. ten Harkel
, Maarten Witsenburg
, Peter L. de Jong
, Luc Jordaens
, Marjolein Wijman
, Arthur A. M. Wilde

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We present a case in which LQTS induced severe prenatal and neonatal arrhythmias. LQT3 was diagnosed (mutation R1623Q). Short-acting beta-blockers were ineffective as well as sotalol and mexiletine in preventing recurrent ventricular arrhythmias. An ICD was implanted at the age of 7 months (weight and length of the infant at implantation 6 kg and 60 cm respectively). Flecainide was prescribed in addition to the ICD implantation. After an appropriate shock the flecainide plasma levels were shown to be subtherapeutic. Readjustment of the flecainide dose resulted in adequate plasma levels. No further shocks occurred during a further 17 months follow-up period. The combination of an active can with a subcutaneous patch proved feasible, and lifesaving shocks occurred at 7 months after implantation. (C) 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved

Original language	English
Pages (from-to)	77-84
Journal	Europace : European pacing, arrhythmias, and cardiac electrophysiology
Volume	7
Issue number	1
DOIs	https://doi.org/10.1016/j.eupc.2004.09.007
Publication status	Published - 2005

Access to Document

10.1016/j.eupc.2004.09.007

Cite this

@article{76b7ab4da37e470db59db6a4e78743bf,

title = "Efficacy of an implantable cardioverter-defibrillator in a neonate with LQT3 associated arrhythmias",

abstract = "We present a case in which LQTS induced severe prenatal and neonatal arrhythmias. LQT3 was diagnosed (mutation R1623Q). Short-acting beta-blockers were ineffective as well as sotalol and mexiletine in preventing recurrent ventricular arrhythmias. An ICD was implanted at the age of 7 months (weight and length of the infant at implantation 6 kg and 60 cm respectively). Flecainide was prescribed in addition to the ICD implantation. After an appropriate shock the flecainide plasma levels were shown to be subtherapeutic. Readjustment of the flecainide dose resulted in adequate plasma levels. No further shocks occurred during a further 17 months follow-up period. The combination of an active can with a subcutaneous patch proved feasible, and lifesaving shocks occurred at 7 months after implantation. (C) 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved",

author = "\{ten Harkel\}, \{Arend D. J.\} and Maarten Witsenburg and \{de Jong\}, \{Peter L.\} and Luc Jordaens and Marjolein Wijman and Wilde, \{Arthur A. M.\}",

year = "2005",

doi = "10.1016/j.eupc.2004.09.007",

language = "English",

volume = "7",

pages = "77--84",

journal = "Europace : European pacing, arrhythmias, and cardiac electrophysiology",

issn = "1099-5129",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Efficacy of an implantable cardioverter-defibrillator in a neonate with LQT3 associated arrhythmias

AU - ten Harkel, Arend D. J.

AU - Witsenburg, Maarten

AU - de Jong, Peter L.

AU - Jordaens, Luc

AU - Wijman, Marjolein

AU - Wilde, Arthur A. M.

PY - 2005

Y1 - 2005

N2 - We present a case in which LQTS induced severe prenatal and neonatal arrhythmias. LQT3 was diagnosed (mutation R1623Q). Short-acting beta-blockers were ineffective as well as sotalol and mexiletine in preventing recurrent ventricular arrhythmias. An ICD was implanted at the age of 7 months (weight and length of the infant at implantation 6 kg and 60 cm respectively). Flecainide was prescribed in addition to the ICD implantation. After an appropriate shock the flecainide plasma levels were shown to be subtherapeutic. Readjustment of the flecainide dose resulted in adequate plasma levels. No further shocks occurred during a further 17 months follow-up period. The combination of an active can with a subcutaneous patch proved feasible, and lifesaving shocks occurred at 7 months after implantation. (C) 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved

AB - We present a case in which LQTS induced severe prenatal and neonatal arrhythmias. LQT3 was diagnosed (mutation R1623Q). Short-acting beta-blockers were ineffective as well as sotalol and mexiletine in preventing recurrent ventricular arrhythmias. An ICD was implanted at the age of 7 months (weight and length of the infant at implantation 6 kg and 60 cm respectively). Flecainide was prescribed in addition to the ICD implantation. After an appropriate shock the flecainide plasma levels were shown to be subtherapeutic. Readjustment of the flecainide dose resulted in adequate plasma levels. No further shocks occurred during a further 17 months follow-up period. The combination of an active can with a subcutaneous patch proved feasible, and lifesaving shocks occurred at 7 months after implantation. (C) 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved

U2 - 10.1016/j.eupc.2004.09.007

DO - 10.1016/j.eupc.2004.09.007

M3 - Article

C2 - 15670972

SN - 1099-5129

VL - 7

SP - 77

EP - 84

JO - Europace : European pacing, arrhythmias, and cardiac electrophysiology

JF - Europace : European pacing, arrhythmias, and cardiac electrophysiology

IS - 1

ER -

Efficacy of an implantable cardioverter-defibrillator in a neonate with LQT3 associated arrhythmias

Abstract

Access to Document

Fingerprint

Cite this